Literature DB >> 23925275

Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine.

Vidyashankara Iyer1, Lei Hu, Carole E Schanté, David Vance, Chrystal Chadwick, Nishant Kumar Jain, Robert N Brey, Sangeeta B Joshi, David B Volkin, Kiran K Andra, James G Bann, Nicholas J Mantis, C Russell Middaugh.   

Abstract

Dominant Negative Inhibitor (DNI) is a translocation-deficient homolog of recombinant protective antigen of Bacillus anthracis that is a candidate for a next generation anthrax vaccine. This study demonstrates that the biophysical characteristics of the DNI protein stored in lyophilized form at 4°C for 8 y were similar to recombinant Protective Antigen (rPA). To provide information on the accelerated stability of DNI, samples in the lyophilized form were subjected to thermal stress (40°C and 70°C for up to 4 weeks) and thoroughly evaluated using various biophysical and chemical characterization techniques. Results demonstrate preserved structural stability of the DNI protein under extreme conditions, suggesting long-term stability can be achieved for a vaccine that employs DNI, as desired for a biodefense countermeasure. Furthermore, the biological activity of the stressed DNI bound to the adjuvant Alhydrogel (®) was evaluated in mice and it was found that the immunogenicity DNI was not affected by thermal stress.

Entities:  

Keywords:  Accelerated Stability; Aluminum Hydroxide; Biophysical characterization; Dominant-Negative Inhibitor; Immunogenicity; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 23925275      PMCID: PMC3981845          DOI: 10.4161/hv.25852

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  23 in total

1.  Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.

Authors:  B R Sellman; M Mourez; R J Collier
Journal:  Science       Date:  2001-04-27       Impact factor: 47.728

Review 2.  Anthrax.

Authors:  T C Dixon; M Meselson; J Guillemin; P C Hanna
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

3.  Characterization of dominant-negative forms of anthrax protective antigen.

Authors:  Ming Yan; R John Collier
Journal:  Mol Med       Date:  2003 Jan-Feb       Impact factor: 6.354

4.  Receptor-specific requirements for anthrax toxin delivery into cells.

Authors:  G Jonah A Rainey; Darran J Wigelsworth; Patricia L Ryan; Heather M Scobie; R John Collier; John A T Young
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

5.  Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine.

Authors:  Ajit Joseph M D'Souza; Kevin D Mar; Joanne Huang; Sumit Majumdar; Brandi M Ford; Beverly Dyas; Robert G Ulrich; Vincent J Sullivan
Journal:  J Pharm Sci       Date:  2012-12-14       Impact factor: 3.534

Review 6.  Anthrax as a biological weapon, 2002: updated recommendations for management.

Authors:  Thomas V Inglesby; Tara O'Toole; Donald A Henderson; John G Bartlett; Michael S Ascher; Edward Eitzen; Arthur M Friedlander; Julie Gerberding; Jerome Hauer; James Hughes; Joseph McDade; Michael T Osterholm; Gerald Parker; Trish M Perl; Philip K Russell; Kevin Tonat
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

7.  Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines.

Authors:  Benedikt A Aulinger; Michael H Roehrl; John J Mekalanos; R John Collier; Julia Y Wang
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

8.  Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.

Authors:  Inge Berthold; Maria-Luz Pombo; Leslie Wagner; Juan L Arciniega
Journal:  Vaccine       Date:  2005-03-14       Impact factor: 3.641

9.  Crystal structure of a complex between anthrax toxin and its host cell receptor.

Authors:  Eugenio Santelli; Laurie A Bankston; Stephen H Leppla; Robert C Liddington
Journal:  Nature       Date:  2004-07-04       Impact factor: 49.962

10.  Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen.

Authors:  Darran J Wigelsworth; Bryan A Krantz; Kenneth A Christensen; D Borden Lacy; Stephen J Juris; R John Collier
Journal:  J Biol Chem       Date:  2004-03-24       Impact factor: 5.157

View more
  5 in total

1.  Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.

Authors:  Kimberly J Hassett; David J Vance; Nishant K Jain; Neha Sahni; Lilia A Rabia; Megan C Cousins; Sangeeta Joshi; David B Volkin; C Russell Middaugh; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2015-01-11       Impact factor: 3.534

2.  Conjugate-like immunogens produced as protein capsular matrix vaccines.

Authors:  Ann Thanawastien; Robert T Cartee; Thomas J Griffin; Kevin P Killeen; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-19       Impact factor: 11.205

3.  Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice.

Authors:  David J Vance; Yinghui Rong; Robert N Brey; Nicholas J Mantis
Journal:  Vaccine       Date:  2014-12-02       Impact factor: 3.641

4.  Binding of the von Willebrand Factor A Domain of Capillary Morphogenesis Protein 2 to Anthrax Protective Antigen Vaccine Reduces Immunogenicity in Mice.

Authors:  Fabiana Freire Mendes de Oliveira; Sireesha Mamillapalli; Srinivas Gonti; Robert N Brey; Han Li; Jarad Schiffer; Arturo Casadevall; James G Bann
Journal:  mSphere       Date:  2020-01-15       Impact factor: 4.389

5.  Constructing and transient expression of a gene cassette containing edible vaccine elements and shigellosis, anthrax and cholera recombinant antigens in tomato.

Authors:  Jafari Davod; Dehghan Nayeri Fatemeh; Hossein Honari; Ramin Hosseini
Journal:  Mol Biol Rep       Date:  2018-09-22       Impact factor: 2.316

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.